Zogenix is committed to researching and developing innovative therapeutic solutions for rare diseases by maintaining transparent relationships with its stakeholders.
We believe that, by working together with medical experts, institutions and patients community, we can contribute to the exchange and advancement of treatments and improve patient care. Therefore, we are committed to pay a reasonable compensation and identify a legitimate business needs for our interactions with healthcare professionals (HCPs), healthcare organisations (HCOs), other relevant decision makers and patient organisations (POs).
As part of our transparency reporting obligations, Zogenix discloses the transfers of value made to healthcare professionals, healthcare organisations and patient organisations based in Europe. These disclosures are reported either in accordance with applicable local national reporting systems or on this European website.
Specific information on the disclosure of transfers of value made to healthcare professionals, healthcare organisations and patient organisations can be found by clicking the relevant country.
In accordance with the terms of the French Sunshine Act or “Loi Bertrand” on transparency of interactions between industries and professionals of the healthcare sector, transfers of value made to HCPs, HCOs and POs based in France as well as information relating to the agreements concluded with these persons and entities are published on the DGS (Department of the Ministry of Health) National Public Platform.
Click here if you would like to know more information on the Zogenix French disclosure.
In accordance with the requirements under the ABPI Code of Practice, to which Zogenix has committed to comply with on a voluntary basis, transfers of value made to HCPs and HCOs based in the United Kingdom are published on the ABPI Disclosure platform. Click here if you would like to know more information on the Zogenix UK disclosure.
Financial contributions made by Zogenix to POs are listed below:
|Patient Organisation 2020 Disclosure Report|
|Patient Organisation Name||Purpose||Description||Amount of Support|
|Dravet Syndrome UK||Charitable Donation||Charitable donation to support Dravet Syndrome UK during funding crisis caused by Covid Pandemic||£ 43625|
You can also access Zogenix’s methodology note for transfers of value made to POs.